Cancer Res Treat.  2020 Oct;52(4):1242-1250. 10.4143/crt.2020.286.

Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea

• Pak S
• You D
• Jeong IG
• Lee DE
• Kim SH
• Joung JY
• Lee KH
• Hong JH
• Kim CS
• Ahn H

• KMID: 2507949
• DOI: http://doi.org/10.4143/crt.2020.286

Abstract

Purpose
This study aimed to examine the causes of death in Korean patients who underwent radical prostatectomy for prostate cancer and investigate the relationship between comorbidity and mortality.
Materials and Methods
We conducted a retrospective multicenter cohort study including 4,064 consecutive patients who had prostate cancer and underwent radical prostatectomy between January 1998 and June 2013. The primary endpoint of this study was all-cause mortality, and the secondary endpoints were cancer-specific mortality (CSM) and other-cause mortality (OCM). Charlson comorbidity index (CCI) was calculated to assess the comorbidities of each patient.
Results
Of 4,064 patients, 446 (11.0%) died during follow-up. The cause of death was prostate cancer in 132 patients (29.6%), other cancers in 121 patients (27.1%), and vascular disease in 57 patients (12.8%) in our cohort. The overall 10-year CSM rate was lower than the OCM rate (4.6% vs. 10.5%). The 10-year CSM rate was lower than the OCM rate in low- to intermediate-risk group patients (1.2% vs. 10.6%), whereas they were similar in high-risk group patients (11.8% vs. 10.1%). In the multivariable analysis, CCI was independently associated with all-cause mortality after radical prostatectomy, regardless of age and pathologic features.
Conclusion
Death from prostate cancer was rare in Korean men who underwent radical prostatectomy. Clinicians should be aware of the possibility of overtreatment of low-risk prostate cancer in men with significant comorbidity. Our findings may help to facilitate counseling and plan management in this patient group.

Keyword

Prostatic neoplasms; Survival; Comorbidity

Figure

• 

  Fig. 1. Survival outcomes of the overall population.

• 

  Fig. 2. Survival outcomes according to the preoperative National Comprehensive Cancer Network risk group.

• 

  Fig. 3. Survival outcomes according to comorbidities and preoperative National Comprehensive Cancer Network risk group. CCI, Charlson comorbidity index.

Reference

References

1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69:363–85.

2. ICECaP Working Group, Sweeney C, Nakabayashi M, Regan M, Xie W, Hayes J, et al. The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst. 2015; 107:djv261.

3. Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016; 13:205–15.

4. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017; 377:132–42.

5. Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE. Current clinical presentation and treatment of localized prostate cancer in the United States. J Urol. 2014; 192:1650–6.

6. Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016; 66:337–50.

7. Daskivich TJ, Kwan L, Dash A, Saigal C, Litwin MS. An age adjusted comorbidity index to predict long-term, other cause mortality in men with prostate cancer. J Urol. 2015; 194:73–8.

8. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117:2058–66.

9. Roder MA, Brasso K, Christensen IJ, Johansen J, Langkilde NC, Hvarness H, et al. Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. BJU Int. 2014; 113:541–7.

10. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998; 83:1180–8.

11. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994; 47:1245–51.

12. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019; 17:479–505.

13. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011; 117:5039–46.

14. Matthes KL, Limam M, Pestoni G, Held L, Korol D, Rohrmann S. Impact of comorbidities at diagnosis on prostate cancer treatment and survival. J Cancer Res Clin Oncol. 2018; 144:707–15.

15. Boehm K, Larcher A, Tian Z, Mandel P, Schiffmann J, Karakiewicz PI, et al. Low other cause mortality rates reflect good patient selection in patients with prostate cancer treated with radical prostatectomy. J Urol. 2016; 196:82–8.

16. Briganti A, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol. 2013; 63:693–701.

17. Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: a population-based retrospective cohort study. Urol Oncol. 2018; 36:309.

18. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, et al. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol. 2012; 62:204–9.

19. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J Urol. 2012; 188:73–83.

20. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009; 57:24–30.

21. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012; 9:652–64.

22. Jeong IG, Dajani D, Verghese M, Hwang J, Cho YM, Hong JH, et al. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: a retrospective cohort study of radical prostatectomy. Urol Oncol. 2016; 34:3.

23. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011; 185:869–75.

24. Bolton DM, Papa N, Ta AD, Millar J, Davidson AJ, Pedersen J, et al. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry. BJU Int. 2015; 116 Suppl 3:66–72.

25. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology. 2015; 85:92–100.

26. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol. 2017; 35:3566–74.

27. Vital Statistics Division; Statistics Korea, Shin HY, Lee JY, Kim JE, Lee S, Youn H, et al. Cause-of-death statistics in 2016 in the Republic of Korea. J Korean Med Assoc. 2018; 61:573–84.

28. Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res. 2012; 18:6742–7.

29. Jeong IG, Yoo S, Lee C, Kim M, You D, Song C, et al. Obesity as a risk factor for unfavorable disease in men with low risk prostate cancer and its relationship with anatomical location of tumor. J Urol. 2017; 198:71–8.

30. Loppenberg B, Friedlander DF, Krasnova A, Tam A, Leow JJ, Nguyen PL, et al. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018; 124:55–64.